Last updated on August 2019

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285) A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor in Patients With Advanced Systemic Mastocytosis


Find a site near you

Start Over